skip to main content

Dapagliflozin thrush — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardEndocrine TherapeuticsDapagliflozin thrushGPhC CRA

A patient using rimegepant for migraine is prescribed clarithromycin for an infection. Which response best reflects the Vydura SmPC?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Query the combination because clarithromycin is a strong CYP3A4 inhibitor and concomitant rimegepant is not recommended

Option D is correct: clarithromycin is a strong CYP3A4 inhibitor and can markedly increase rimegepant exposure, so concomitant use is not recommended. Option A cannot overcome enzyme inhibition by spacing. Option E invents an unlicensed half dose. Option C ignores the medicine interaction. Option B makes an unauthorised antibiotic change and erythromycin still requires interaction assessment as a moderate inhibitor.

Reference: Vydura SmPC: https://www.medicines.org.uk/emc/product/13928/smpc